Premium
All‐ trans ‐retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia
Author(s) -
Quezada Gerardo,
Kopp Lisa,
Estey Elihu,
Wells Robert J.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21529
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , medicine , anthracycline , retinoic acid , tretinoin , blood cancer , myeloid leukemia , chemotherapy , cancer research , leukemia , combination therapy , oncology , cancer , apoptosis , biochemistry , chemistry , gene , breast cancer
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML). Treatment of pediatric APL is based on the combination of all‐ trans ‐retinoic acid (ATRA), an anthracycline and cytosine arabinoside. Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excellent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy. There is little data on combination therapy with ATRA and ATO in pediatric APL. We present a case of an adolescent male with APL who was treated using ATRA and ATO without conventional chemotherapy agents. Pediatr Blood Cancer 2008;51:133–135. © 2008 Wiley‐Liss, Inc.